Novartis AG · SIX:NOVN

Novartis — LODH Swiss Equities Conference, London 2006

31 slides from Novartis's conference presentation, May 3, 2006

  1. Slide 1: Growth Platforms for a Changing Health Care Environment

    Growth Platforms for a Changing Health Care Environment Raymund Breu Chief Financial Officer, Novartis AG Steffen Roellinger Global Head Project Management and Head of Development Operations Europe, Novartis Pharma LODH Swiss Equities Conference, London, May 3 2006 The following information contains

  2. Slide 2: Strong Start to 2006 with Excellent Sales and Earnings Growth

    Agenda • Q1 2006 Novartis Group Performance • Business Environment and Strategy • Novartis Pharmaceuticals Performance • Pharmaceuticals Pipeline • Outlook 3 LODH Conference, Novartis London, May 2006 Strong Start to 2006 with Excellent Sales and Earnings Growth Performance • Q1 Group net sales up +

  3. Slide 3: Operating and Net Income Expansion Outpace Sales Growth

    Operating and Net Income Expansion Outpace Sales Growth – EPS up 32% 3 M 2006 3 M 2005 in % USD in % LC Net sales 8 301 7 341 +13 +17 Operating income 2 202 1 680 +31 as % of net sales 26.5 22.9 Net income 1 956 1 477 +32 as % of net sales 23.6 20.1 Free Cash Flow 373 - 269 * EPS (USD) 0.83 0.63 +32

  4. Slide 4: Strong Growth and Market Share Gains By All Divisions

    Strong Growth and Market Share Gains By All Divisions 3 M 2006 net sales: USD 8 301 m Net sales in % by 3 M 2006 % net sales growth division 9 Consumer Pharmaceuticals 5 Health 22 88 Sandoz 78 17 61 7 Consumer Health Sandoz 4 17 Pharmaceuticals Group 13 LC USD 7 LODH Conference, Novartis London, May

  5. Slide 5: Group Operating Margin Reaches 26.5% in Q1 2006

    Group Operating Margin Reaches 26.5% in Q1 2006 Operating margins in % 3 M 2006 3 M 2005 32.2 28.5 25.2 26.5 22.9 16.6 16.4 13.7 Pharma- Sandoz Consumer Group ceuticals Health 9 LODH Conference, Novartis London, May 2006 Acquisition Related Charges Offset Productivity Improvements % pt change Q1 200

  6. Slide 6: Net Income Increases 32%; Cash Flow From Operations

    Net Income Increases 32% Due to Strong Business Expansion and One-time Gain in USD m 3 M 2006 3 M 2005 Change in % USD Operating income 2 202 1 680 +31 Result from associated companies 104 33 +215 Financial income, net 50 45 +11 Income before taxes 2 356 1 758 +34 Taxes - 400 - 281 +42 Net income 1

  7. Slide 7: Four Fundamental Trends Drive Growth in Health Care and Medicines

    Agenda • Q1 2006 Novartis Group Performance • Business Environment and Strategy • Novartis Pharmaceuticals Performance • Pharmaceuticals Pipeline • Outlook 13 LODH Conference, Novartis London, May 2006 Four Fundamental Trends Drive Growth in Health Care and Medicines • Aging population with increasi

  8. Slide 8: Industry Faces Challenges; Medicare Part D Enrollment

    Industry Faces Challenges • Governments and payors aggressive in managing costs − Price cuts, discounts, co-pays, formularies and other cost containment measures − Parallel importing − Fast generics penetration • R&D productivity • Pharmaceutical industry reputation − Transparency − Access to medici

  9. Slide 9: Strategy Focused on Customer Needs

    Strategy Focused on Customer Needs • Leadership in better medicines − R&D powerhouse − Preferred partner for in-licensing • Building and strengthening new growth platforms − Biopharmaceuticals − Generics − Vaccines • Reliable and trusted partner to patients, customers and authorities 17 LODH Confere

  10. Slide 10: Priorities for Investments and Acquisitions

    Priorities for Investments and Acquisitions with a Stringent and Simple Logic Investment rules 1 Organic growth as foundation • Focus on health care 1 Own pipeline • Reach leadership position or Priority operate with clear success 2 In-licensing & partnering • No conflicting businesses 3 Smaller • G

  11. Slide 11: Pharmaceuticals - Key Messages

    Agenda • Q1 2006 Novartis Group Performance • Business Environment and Strategy • Novartis Pharmaceuticals Performance • Pharmaceuticals Pipeline • Outlook 21 LODH Conference, Novartis London, May 2006 Pharmaceuticals - Key Messages • High single-digit sales growth ahead of market • Strong performan

  12. Slide 12: Strong Pharma Net Sales Expansion

    Strong Pharma Net Sales Expansion 3M 2006 Growth in % vs. 2005 USD m USD LC Net sales 5 052 5 9 Operating income 1 626 19 Return on sales 32.2% Employees2 at period end 49 696 2 Global market share up from 3.80 to 3.89%1 1 IMS 29 Countries Feb YTD 2006 2 In full-time equivalents 23 LODH Conference,

  13. Slide 13: Novartis Continues to Grow Ahead of Market

    Novartis Continues to Grow Ahead of Market Global quarterly value growth rates, in % Health care market Novartis Pharma 11.3 10.4 9.6 7.7 8.1 8.3 7.8 7.3 6.9 7.3 7.6 6.5 6.4 6.4 5.3 5.5 5.5 5.1 1 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2004 2005 2006 1 Q1: Jan + Feb Source: IMS 29 Countries 25 LODH Conference, N

  14. Slide 14: Strong In-Market Brand Performance

    Strong In-Market Brand Performance Top 10 product net sales 3M 2006 in USD m1 Growth in LC vs. PY Diovan® 939 +16% Glivec®2 559 +18% Zometa® 319 +10% Lotrel® 295 +28% Sandostatin® 216 +1% Neoral® 214 0% Lamisil® 200 -17% Lescol® 178 +9% Trileptal® 166 +10% Voltaren® 160 +3% 1 Adjusted for US sale re

  15. Slide 15: Key Factors Driving Future Growth; 2006 Pharmaceuticals Outlook

    Key Factors Driving Future Growth New indications Dose optimization Extended survival • Glioblastoma • Leveraging recent • Sustained efficacy multiforme label updates and tolerability (newly-diagnosed • Trial ongoing to • 90% overall and recurrent) assess Glivec survival2 at 4 ½ • Adjuvant GIST 800m

  16. Slide 16: A Focused Portfolio in Attractive Market Segments

    Agenda • Q1 2006 Novartis Group Performance • Business Environment and Strategy • Novartis Pharmaceuticals Performance • Pharmaceuticals Pipeline • Outlook 31 LODH Conference, Novartis London, May 2006 A Focused Portfolio in Attractive Market Segments Phase Business unit / Business franchise I II II

  17. Slide 17: Attractive Late-Stage Pipeline Progressing Well

    Attractive Late-Stage Pipeline Progressing Well Phase Status Galvus®1 (type 2 diabetes) Reg File accepted by FDA in March 06 Rasilez®1 (hypertension) Reg File accepted by FDA in April 06 Exforge®1 (hypertension) Reg Filed in EU in March, US filing accepted in April 06 Lucentis™ (wet AMD2) Reg Filed

  18. Slide 18: Galvus Reduction in HbA1c

    Galvus Demonstrates Excellent, Dose-proportional Reduction in HbA1c Duration: 12 weeks Galvus 20 mg Galvus 50 mg Galvus 100 mg (n= 71) (n=72) (n=76) 0 Mean HbA1c (%) Difference to Placebo -0.2 -0.4 -0.6 -0.8 -0.82* -1.0 -0.95* -1.2 -1.2* -1.4 Baseline HbA1c 7.43 7.40 7.37 Source: Study 1202 data on

  19. Slide 19: Galvus Non-Inferiority vs. Rosiglitazone

    Galvus® (vildagliptin) Met Primary Endpoint of Non-Inferiority vs. rosiglitazone Change in HbA1c (%) at 24 weeks Galvus® 50 mg bid (n=166) rosiglitazone 8 mg qd (n=88) Mean HbA1c baseline = 10% 0.0 -0.2 -0.4 -0.6 -0.8 -1.0 -1.2 -1.4 -1.6 -1.8 -2.0 -1.82 -1.86 Galvus® is as effective as rosiglitazone

  20. Slide 20: Galvus Cardiovascular Safety Profile

    Galvus® (vildagliptin) Shows Good Cardiovascular Safety Profile • Overall cardiac adverse events − Incidence 2.4%, lower than metformin and similar to placebo • Hypertension − Adverse events reports for hypertension low (3.4%), lower than for metformin and similar to placebo − No propensity in subgr

  21. Slide 21: Galvus Better Tolerated than Metformin

    Galvus Is Better Tolerated than Metformin AEs of special interest Galvus 100 mg (%) metformin 2 000 mg (%) (n=526) (n=254) Hypertension 3.7 4.8 Edema 2.5 3.6 Diarrhea 6.0 26.2 Paresthesia 0.8 2.0 Nausea 3.3 10.3 Myalgia 2.3 0.8 Hypoglycemia 0.6 0.4 ECG1 abnormalities 11.0 12.0 1 Electrocardiogram So

  22. Slide 22: Rasilez: Next Generation in Blood Pressure Control

    Rasilez® (aliskiren*) – Next Generation in Blood Pressure and Vascular Disease Control • First oral renin inhibitor for hypertension Renin • Efficacious in monotherapy and excellent candidate for combination therapy • Potential for improved end-organ protection via control of plasma renin activity •

  23. Slide 23: Mean Ambulatory BP Reduction over 24 Hours

    Mean Ambulatory BP Shows Significant and Sustained Reduction over Entire 24 hours Trough-to-peak ratio Change from baseline at week 8 Placebo, n=165 in mean ambulatory DBP1 (mm Hg) 150 mg, n=172 64% 300 mg, n=169 98% 10 600 mg, n=166 97% 5 0 -5 -10 -15 2 4 6 8 10 12 14 16 18 20 22 24 1 Post-dosing (

  24. Slide 24: Rasilez Superior Efficacy Compared to Ramipril

    Rasilez® (aliskiren) Offers Superior Efficacy Compared to ramipril in Systolic Blood Pressure… Mean change in systolic blood pressure from baseline at endpoint (week 8) mmHg ramipril Rasilez® Rasilez® / ramipril 10 mg 300 mg 300/10 0 -10.0 -11.0 n = 459 -12.0 -12.0 -13.0 -14.0 n = 282 -15.0 -14.7 -1

  25. Slide 25: Rasilez Mono- and Combination Therapy

    Rasilez® Provides Significant BP Reduction when Added to amlodipine with Reduced Incidence of Edema Mean change in blood pressure from baseline at week 6 mmHg amlodipine amlodipine Rasilez®1 150 mg 5 mg 10 mg + amlodipine 5 mg n=180 n=178 n=187 0 dia dia sys sys sys dia -4 -5 −4.8 −5.0 -6 -7 -8 −8.0

  26. Slide 26: Exforge; Strong CVM Presence at Key Events in 2006

    Exforge (valsartan / amlodipine) – A Dual Combination Product of the Most Prescribed Antihypertensives • Exforge development was successfully completed − Clinical program included over 5 000 patients • Systolic blood pressure reduction up to 36 mmHg1 • Diastolic blood pressure reduction up to 29 mmH

  27. Slide 27: FTY720 in Multiple Sclerosis – Efficacy Over 12 Months

    FTY720 in Multiple Sclerosis – Strong Efficacy Maintained Over 12 Months MRI1 – Proportion of patients free of Gd2-enhancing (lesions by visit) % Lesion-free patients FTY720 1.25 mg (n=92) FTY720 5 mg (n=93) Placebo / FTY 1.25 mg (n=40) Placebo / FTY 5 mg (n=43) 100 90 89% 83% 80 83% 70 73% 60 50 Pl

  28. Slide 28: FTY720 Safety and Phase III Progress

    Good Safety Profile of FTY720 in Multiple Sclerosis • FTY720 was safe and well tolerated over 12 months, no unexpected adverse events as compared to 6-months interim analysis • No confirmed cases of macular edema to date in the MS population • No confirmed cases of PML1 to date • All patients contin

  29. Slide 29: Strong Newsflow in 2006; Planned Filings

    Strong Newsflow in 2006 H1 H2 • Exforge®1 PhIII • Aclasta®2 PMO-T PhIII Data • Rasilez®1 PhIII • FTY720 MS PhII (24 months) • Galvus®1 PhIII • AMN107 PhII3 • Sebivo PhIII 9 ®1 • FTY720 MS Ph II (18 months) 9 • NMC283 PhII9 • SOM230 PhII • Rasilez®1 (US) 9 • Rasilez®1 (EU) Filings • Galvus®1 (US) 9 •

  30. Slide 30: Chiron Reporting Update

    Agenda • Q1 2006 Novartis Group Performance • Business Environment and Strategy • Novartis Pharmaceuticals Performance • Pharmaceuticals Pipeline • Outlook 59 LODH Conference, Novartis London, May 2006 Chiron Reporting Update • Deal completed on April 20th • Post acquisition results and estimated Ba

  31. Slide 31: Outlook for 2006 – Stronger Competitive Position

    Outlook for 2006 – Stronger Competitive Position Excluding impact of Chiron transaction and barring unforeseen events • Financial outlook for 2006 reaffirmed • High single-digit sales growth (in LC) • Continued market share gains • Sustained positive pipeline news flow • Record operating and net inc

Novartis — LODH Swiss Equities Conference, London 2006 on 6ix